

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086448 A1

(51) International Patent Classification: **A61K 38/04**,
39/395, 38/08, A61P 13/12, 9/10, 11/00

[AU/AU]; 31 Glen Ross Road, Sinnamon Park, Queens-
land 4073 (AU).

(21) International Application Number: PCT/AU03/00415

(74) Agent: **GRIFFITH HACK**; 509 St Kilda Road, Mel-
bourne, Victoria 3004 (AU).

(22) International Filing Date: 7 April 2003 (07.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PS 1606 8 April 2002 (08.04.2002) AU

(71) Applicant (for all designated States except US):
PROMICS PTY LIMITED [AU/AU]; BUILDING
64, PHYSIOLOGY & PHARMACOLOGY DEPT, UNI-
VERSITY OF QUEENSLAND, ST LUCIA, Queensland
4072 (AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TAYLOR, Stephen**,
Maxwell [AU/AU]; 17 Perdita Street, Bellbird Park,
Queensland 4300 (AU). **SHIELS, Ian, Alexander**
[AU/AU]; 17 Sherlock Road, Muirlea Road, Muirlea,
Queensland 4306 (AU). **BROWN, Lindsay, Charles**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.


WO 03/086448 A1

(54) Title: USE OF C5A RECEPTOR ANTAGONIST IN THE TREATMENT OF FIBROSIS

(57) Abstract: This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment the antagonist is a C5a receptor antagonist, more preferably a cyclic peptide antagonist of the C5a receptor. In particular the invention provides a method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.

CLAIMS

1. A method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of
5 administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.
2. A method according to claim 1, in which the antagonist is a C5a receptor antagonist.
- 10 3. A method according to claim 1 or claim 2, in which the antagonist is a peptide or a peptidomimetic compound.
4. A method according to claim 3, in which the antagonist is a cyclic peptide or a cyclic peptidomimetic
15 compound.
5. A method according to any one of claims 1 to 3, in which the antagonist
 - (a) is an antagonist of a G protein-coupled receptor,
 - 20 (b) has substantially no agonist activity, and
 - (c) is a cyclic peptide or peptidomimetic compound of formula I



where A is H, alkyl, aryl, NH₂, NH-alkyl,

N(alkyl)₂, NH-aryl, NH-acyl, NH-benzoy, NHSO₃, NHSO₂-alkyl, NHSO₂-aryl, OH, O-alkyl, or O-aryl;

B is an alkyl, aryl, phenyl, benzyl, naphthyl or indole group, or the side chain of a D- or L-amino acid such as L-phenylalanine or L-phenylglycine, but is not the side chain of glycine, D-phenylalanine, L-homophenylalanine, L-tryptophan, L-homotryptophan, L-tyrosine, or L-homotyrosine;

C is a small substituent, such as the side chain of a D-, L- or homo-amino acid such as glycine, alanine, leucine, valine, proline, hydroxyproline, or thioproline, but is preferably not a bulky substituent such as isoleucine, phenylalanine, or cyclohexylalanine;

D is the side chain of a neutral D-amino acid such as D-Leucine, D-homoleucine, D-cyclohexylalanine, D-homocyclohexylalanine, D-valine, D-norleucine, D-homonorleucine, D-phenylalanine, D-tetrahydroisoquinoline, D-glutamine, D-glutamate, or D-tyrosine, but is preferably not a small substituent such as the side chain of glycine or D-alanine, a bulky planar side chain such as D-tryptophan, or a bulky charged side chain such as D-arginine or D-Lysine;

E is a bulky substituent, such as the side chain of an amino acid selected from the group consisting of L-phenylalanine, L-tryptophan and L-homotryptophan, or is L-1-naphthyl or L-3-benzothienyl alanine, but is not the side chain of D-tryptophan, L-N-methyltryptophan, L-homophenylalanine, L-2-naphthyl L-tetrahydroisoquinoline, L-cyclohexylalanine, D-leucine, L-fluorenylalanine, or L-histidine;

F is the side chain of L-arginine, L-homoarginine, L-citrulline, or L-canavanine, or a bioisostere thereof, ie. a side chain in which the terminal guanidine or urea group is retained, but the carbon backbone is replaced by a group which has different structure but is such that the side chain as a whole reacts with the target protein in the

same way as the parent group; and

X is $-(CH_2)_nNH-$ or $(CH_2)_nS-$, where n is an integer of from 1 to 4, preferably 2 or 3; $-(CH_2)_2O-$; $-(CH_2)_3O-$; $-(CH_2)_3-$; $-(CH_2)_4-$; $-CH_2COCHRNH-$; or
5 $-CH_2-CHCOCHRNH-$, where R is the side chain of any common or uncommon amino acid.

6. A method according to claim 5, in which A is an acetamide group, an aminomethyl group, or a substituted or unsubstituted sulphonamide group.

10 7. A method according to claim 6, in which A is a substituted sulphonamide, and the substituent is an alkyl chain of 1 to 6, preferably 1 to 4 carbon atoms, or a phenyl or tolyl group.

8. A method according to any one of claims 1 to 6, in
15 which the antagonist is a C5a receptor antagonist which has antagonist activity against C5aR, and has no C5a agonist activity.

9. A method according to any one of claims 1 to 7, in
20 which the compound has a receptor affinity $IC_{50} < 25 \mu M$, and an antagonist potency $IC_{50} < 1 \mu M$.


10. A method according to any one of claims 1 to 8,
in which the compound is selected from the group consisting
of compounds 1 to 6, 10 to 15, 17, 19, 20, 22, 25, 26, 28,
30, 31, 33 to 37, 39 to 45, 47 to 50, 52 to 58 and 60 to 70
25 described in International patent application
No. PCT/AU02/01427.

11. A method according to claim 10, in which the
compound is PMX53 (compound 1), compound 33, compound 60 or
compound 45.

30 12. A method according to claim 10, in which the
compound is PMX53, having the formula

5

10



15

13. The use of a C5a receptor antagonist for the manufacture of a medicament for use in the treatment of a fibrotic condition.